is there no evidence that antipsychotics help ocd when added early to an ssri?
“there's no evidence that second-generation anti-psychotics had any benefit at all early on in OCD treatment.”
a guest, Dr. Robert Hudak, professor of psychiatry at the University of Pittsburgh said on Psychopharmacology and Psychiatry Updates, 2026-10-23, at 02:30. hear it in context →
the episode: Second-Generation Antipsychotics for OCD Augmentation (at 02:30). we link the show's own page; we do not re-host audio.
first, the part that holds
most of the trial evidence for adding a second-generation antipsychotic to an ssri in ocd comes from people who had already failed an adequate ssri trial, and the standard advice is to give the ssri about three months before adding anything. the one early trial of olanzapine, added after only eight weeks of fluoxetine, found no extra benefit.
what we found when we went and looked
we found one published randomized, double-blind, placebo-controlled trial that tests exactly what the claim says has no evidence. 76 people with ocd who were not on medication and not treatment-resistant got citalopram plus either quetiapine or placebo from the start, for 10 weeks. symptom scores fell more with quetiapine (11.9 vs 7.8 points on the y-bocs, p = .009), and more people responded (69% vs 41%, p = .019). that is a small, single, unreplicated trial with more side-effect dropouts on quetiapine (8 vs 2), so the evidence is thin and contested. but it exists, so "no evidence of any benefit at all" does not hold as stated. the speaker's practical point, that the early-use evidence is weak and guidelines reserve augmentation for people who have not responded, is better supported than the absolute wording.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| there is no trial evidence that a second-generation antipsychotic gives any benefit in ocd when started early, alongside an ssri | false | a 10-week double-blind rct (n=76, drug-free or drug-naive, treatment-refractory patients excluded) found citalopram plus quetiapine beat citalopram plus placebo: y-bocs drop 11.9 vs 7.8 (p=.009), response 69% vs 41% (p=.019). limitation: single site, single trial, not replicated in what we found, and 8 vs 2 discontinued for adverse effects. [1] |
| an early trial of adding an antipsychotic to an ssri found no added benefit | confirmed | after an 8-week open fluoxetine phase, a 6-week placebo-controlled trial adding olanzapine in people who had not responded found both groups improved, with no added advantage for olanzapine. limitation: 44 participants, short trial, a different drug from the positive trial. [2] |
| the evidence base supports waiting about three months on an ssri before adding an antipsychotic | confirmed | a 2006 systematic review (9 trials, 278 participants) found augmentation helped refractory ocd (absolute risk difference 0.22). it advised at least 3 months of maximally tolerated ssri first, because 25.6% responded to continued ssri alone. this predates the 2009 early trial. [3] |
| later meta-analysis of antipsychotic augmentation covers refractory patients, not early treatment | confirmed | a 2014 meta-analysis required at least one adequate ssri trial (at least 8 weeks) and did not include the 2009 early quetiapine trial. it found evidence for risperidone and aripiprazole, and none for quetiapine or olanzapine, in refractory ocd. it flagged trials with only 8 weeks of prior ssri as a source of bias. [4] |
both directions
for the speaker: the bulk of the antipsychotic-augmentation evidence in ocd comes from people who had failed an ssri, not from early treatment. the one other early-ish trial (olanzapine added after 8 weeks of fluoxetine) found no added benefit. a systematic review advised at least three months of ssri treatment first, because about a quarter of people respond to staying on the ssri alone. the 2014 meta-analysis that informs current practice left out the early quetiapine trial and found no evidence for quetiapine or olanzapine even in refractory patients. the positive early trial is small, single, and had more side-effect dropouts on the antipsychotic.
against: the claim is absolute ("no evidence," "any benefit at all"). a randomized, double-blind, placebo-controlled trial tested an antipsychotic (quetiapine) started at the same time as an ssri (citalopram) in non-refractory, medication-free patients. it found a statistically significant benefit on both the main symptom score and response rate. weak, unreplicated or outweighed evidence is not the same thing as no evidence.
what this cannot say
we did not run a full systematic search, so other early-augmentation trials (positive or negative) may exist that we did not read. we read abstracts and one open-access review, not full trial reports, so we could not check blinding, the method used for dropouts, or funding. "early on" is vague: the speaker may mean the first weeks of an ssri, the first 8 to 12 weeks, or first-line treatment generally, and the evidence differs across those. the positive trial used one drug at fairly high doses (citalopram 60 mg, quetiapine 300-450 mg), so it says nothing about other second-generation antipsychotics. we only have the quoted sentence, not the speaker's surrounding context.
sources, each one fetched and read
- University Medical Centre Utrecht group. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70(7):1001-8. PMID 19497245 What we read there: drug-free or drug-naive patients randomized to citalopram 60 mg/day plus quetiapine 300-450 mg/day or placebo for 10 weeks; y-bocs reduction 11.9 vs 7.8 (p = .009); response 69% vs 41% (p = .019); 8 vs 2 discontinued for adverse effects; 'the combination of quetiapine and citalopram was more effective than citalopram alone ... in treatment-naive or medication-free ocd patients.' Fetched 2026-10-25 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/19497245/
- A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55(5):553-5. PMID 15023585 What we read there: after an 8-week open-label fluoxetine trial, a 6-week randomized phase found both groups improved and 'no additional advantage of adding olanzapine' over continued fluoxetine. Fetched 2026-10-25 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/15023585/
- A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006. PMID 16585942 What we read there: 9 studies, 278 participants; absolute risk difference 0.22 (95% ci 0.13-0.31) favoring augmentation; 'patients should be treated with at least 3 months of maximal-tolerated therapy of an sri before initiating antipsychotic augmentation owing to the high rate of treatment response to continued sri monotherapy (25.6%).' Fetched 2026-10-25 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/16585942/
- Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317. PMC4262998 What we read there: inclusion required at least one adequate ssri trial at maximum tolerated dose for at least 8 weeks; found no evidence for quetiapine or olanzapine; risperidone and aripiprazole 'can be used cautiously at a low dose as an augmentation agent in non-responders'; the 2009 early quetiapine trial is not among the included studies. Fetched 2026-10-25 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC4262998/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam